Press Releases

April 26, 2022

ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy

November 8, 2021

ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models

September 14, 2021

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

July 19, 2021

ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery

Reveal more

In the news

March 8, 2022

The "Dark Genome" with Dr. Rosana Kapeller-Lieberman  |  GV "Theory and Practice" podcast

September 10, 2020

Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry  |  MassBio

Reveal more

Publications and presentations

April 20, 2022

Human endogenous retrovirus-k (HERV-K) reverse transcriptase (RT) forms an asymmetric homodimer reminiscent of HIV-1 RT  |  Cold Spring Harbor Laboratory: Fifty Years of Reverse Transcriptase

March 23, 2022

Reverse transcriptase inhibition disrupts repeat element life cycle in colorectal cancer  |  Cancer Discovery